4D Molecular Therapeutics Profit Margin

The latest profit margin for FDMT is -201.41% as of June 2026. That compares with -1225900.0% in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside 4D Molecular Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FDMT's profit margin moved from -1225900.0% to -201.41% — a 100.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 4D Molecular Therapeutics's valuation or profitability profile.

Against Healthcare companies, FDMT currently prints -201.41% for profit margin, while the sector average sits near 13.89%. That is roughly 1549.7% below the sector mean. Large gaps often invite a closer look at 4D Molecular Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively 4D Molecular Therapeutics converts resources into returns. At -201.41%, FDMT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1225900.0% in the prior-year period — up 100.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FDMT's profit margin (-201.41%), review year-over-year change from -1225900.0%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.